| 000 | 01403 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250513031056.0 | ||
| 264 | 0 | _c19940922 | |
| 008 | 199409s 0 0 eng d | ||
| 022 | _a0250-7005 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aButer, J | |
| 245 | 0 | 0 |
_aDose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma. _h[electronic resource] |
| 260 |
_bAnticancer research _c |
||
| 300 |
_a1325-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aDacarbazine _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOndansetron _xadministration & dosage |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 700 | 1 | _aSleijfer, D T | |
| 700 | 1 | _aWillemse, P H | |
| 700 | 1 | _avan der Graaf, W T | |
| 700 | 1 | _ade Vries, E G | |
| 700 | 1 | _aSchraffordt Koops, H | |
| 700 | 1 | _aMulder, N H | |
| 773 | 0 |
_tAnticancer research _gvol. 14 _gno. 3B _gp. 1325-8 |
|
| 999 |
_c7520152 _d7520152 |
||